<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003764.pub2" GROUP_ID="MUSKINJ" ID="958501121711440110" MERGED_FROM="" MODIFIED="2009-08-10 18:13:36 +0200" MODIFIED_BY="Lindsey Elstub" NOTES="&lt;p&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;Date last edited when imported: 05/06/2003 - from Richard&lt;br&gt;Date last edited when imported: 11/11/2003 - from Bill&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-08-08 10:46:30 +1200" NOTES_MODIFIED_BY="Lesley " REVIEW_NO="082" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2009-08-10 18:13:36 +0200" MODIFIED_BY="Lindsey Elstub">
<TITLE>Antibiotics for preventing infection in open limb fractures</TITLE>
<CONTACT MODIFIED="2009-08-10 18:13:36 +0200" MODIFIED_BY="Lindsey Elstub"><PERSON ID="15068" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Gosselin</LAST_NAME><EMAIL_1>froggydoc@comcast.net</EMAIL_1><ADDRESS><DEPARTMENT>c/o Cochrane Bone, Joint and Muscle Trauma Group</DEPARTMENT><ORGANISATION>University of Manchester</ORGANISATION><ADDRESS_1>School of Translational Medicine</ADDRESS_1><ADDRESS_2>2nd Floor Stopford Building, Oxford Road</ADDRESS_2><CITY>Manchester</CITY><ZIP>M13 9PT</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-08-10 18:13:36 +0200" MODIFIED_BY="Lindsey Elstub"><PERSON ID="15068" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Gosselin</LAST_NAME><EMAIL_1>froggydoc@comcast.net</EMAIL_1><ADDRESS><DEPARTMENT>c/o Cochrane Bone, Joint and Muscle Trauma Group</DEPARTMENT><ORGANISATION>University of Manchester</ORGANISATION><ADDRESS_1>School of Translational Medicine</ADDRESS_1><ADDRESS_2>2nd Floor Stopford Building, Oxford Road</ADDRESS_2><CITY>Manchester</CITY><ZIP>M13 9PT</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="8053" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ian</FIRST_NAME><LAST_NAME>Roberts</LAST_NAME><POSITION>Professor of Epidemiology &amp; Public Health</POSITION><EMAIL_1>ian.roberts@lshtm.ac.uk</EMAIL_1><URL>http://injuries.cochrane.org</URL><ADDRESS><DEPARTMENT>Cochrane Injuries Group</DEPARTMENT><ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION><ADDRESS_1>North Courtyard</ADDRESS_1><ADDRESS_2>Keppel Street</ADDRESS_2><CITY>London</CITY><ZIP>WC1E 7HT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7958 8128</PHONE_1><FAX_1>+44 20 7299 4663</FAX_1></ADDRESS></PERSON><PERSON ID="4649" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>William</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Gillespie</LAST_NAME><POSITION>Emeritus Professor</POSITION><EMAIL_1>bill.gillespie@hyms.ac.uk</EMAIL_1><EMAIL_2>bill.gillespie@yahoo.co.nz</EMAIL_2><ADDRESS><DEPARTMENT>Hull York Medical School</DEPARTMENT><ORGANISATION>University of Hull</ORGANISATION><ADDRESS_1>Cottingham Road</ADDRESS_1><CITY>Hull</CITY><ZIP>HU6 7RX</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-08-07 02:49:21 +1200" MODIFIED_BY="Lindsey Elstub">
<UP_TO_DATE>
<DATE DAY="28" MONTH="7" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="7" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="10" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2009-07-30 02:03:29 +1200" MODIFIED_BY="Lindsey Elstub">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-07-30 02:03:29 +1200" MODIFIED_BY="Lindsey Elstub">
<DATE DAY="28" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>Search updated to July 2009 and one new trial (Stevenson 2003) included. Comparison with other reviews updated. Consequential changes to text entered. No overall change to conclusions but additional subgroup analysis conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-03-26 05:01:59 +1300" MODIFIED_BY="Lindsey Elstub">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-26 05:01:59 +1300" MODIFIED_BY="Lindsey Elstub">
<DATE DAY="25" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-26 04:27:49 +1200" MODIFIED_BY="Lindsey Elstub">
<DATE DAY="29" MONTH="10" YEAR="2003"/>
<DESCRIPTION>
<P>First review version published</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-07 15:28:19 +1200" MODIFIED_BY="Lesley ">
<SUMMARY MODIFIED="2009-08-04 22:37:23 +1200" MODIFIED_BY="Helen HG Handoll">
<TITLE MODIFIED="2008-09-25 23:57:43 +1200" MODIFIED_BY="[Empty name]">Antibiotics for preventing infection in open limb fractures</TITLE>
<SUMMARY_BODY MODIFIED="2009-08-04 22:37:23 +1200" MODIFIED_BY="Helen HG Handoll">
<P>Wound and bone infections are common complications following open fractures of the limbs. For more than 20 years in developed countries, the use of antibiotics has been a part of a standard management protocol that also includes washing the wound (irrigation), cleaning up the wound and fracture (surgical debridement), and stabilisation of the fracture, as required. This review, which included data from 1106 participants in eight trials, found that antibiotics are effective in decreasing the incidence of wound infections, as compared with no antibiotics or placebo. No studies reporting bone infection or long-term ill health (morbidity) were identified.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-08-04 22:31:38 +1200" MODIFIED_BY="Helen HG Handoll">
<ABS_BACKGROUND MODIFIED="2009-05-22 15:38:11 +1200" MODIFIED_BY="[Empty name]">
<P>Wound and bone infections are frequently associated with open fractures of the extremities and may add significantly to the resulting morbidity. The administration of antibiotics is routinely practised in developed countries as an adjunct to a comprehensive management protocol that also includes irrigation, surgical debridement and stabilisation when indicated, and is thought to reduce the frequency of infections.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-08-04 22:29:55 +1200" MODIFIED_BY="Helen HG Handoll">
<P>To review the evidence for the effectiveness of antibiotics in the initial treatment of open fractures of the limbs.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-07-29 14:51:29 +1200" MODIFIED_BY="Lesley ">
<P>We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (26 July 2009), Clinical Trials (<I>The Cochrane Library</I> 2009, Issue 3), MEDLINE (1950 to July 2009), EMBASE (1980 to 2009 Week 30), LILACS (1992 to July 2009), International Pharmaceutical Abstracts (1970 to July 2009), and reference lists of articles. We handsearched proceedings of the American Academy of Orthopaedic Surgeons (1980 to 2001), the Orthopaedic Trauma Association (1990 to 2001) and the Société Internationale de Chirurgie Orthopedique et Traumatologique (1980 to 2001). We also contacted published researchers in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised or quasi-randomised controlled trials involving: participants - people of any age with open fractures of the limbs; intervention - antibiotic administered before or at the time of primary treatment of the open fracture compared with placebo or no antibiotic; outcome measures - early wound infection, chronic drainage, acute or chronic osteomyelitis, delayed unions or non-unions, amputations and deaths.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-07-22 02:35:46 +1200" MODIFIED_BY="Lindsey Elstub">
<P>Two review authors independently screened papers for inclusion, assessed trial quality using an eight item scale, and extracted data. Additional information was sought from three trialists. Pooled data are presented graphically.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-08-04 22:31:38 +1200" MODIFIED_BY="Helen HG Handoll">
<P>Data from 1106 participants in eight studies were analysed. The use of antibiotics had a protective effect against early infection compared with no antibiotics or placebo (risk ratio 0.43 (95% confidence interval (CI) 0.29 to 0.65); absolute risk reduction 0.07 (95% CI 0.03 to 0.10). There were insufficient data in the included studies to evaluate other outcomes.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-03-22 13:27:10 +1300" MODIFIED_BY="[Empty name]">
<P>Antibiotics reduce the incidence of early infections in open fractures of the limbs. Further placebo controlled randomised trials are unlikely to be justified in middle and high income countries, except for open fractures of the fingers. Further research is necessary to the determine the avoidable burden of morbidity in countries where antibiotics are not used routinely in the management of open fractures.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-08-07 15:28:19 +1200" MODIFIED_BY="Lesley ">
<BACKGROUND MODIFIED="2009-08-04 22:41:52 +1200" MODIFIED_BY="Helen HG Handoll">
<P>The use of antibiotics in the initial treatment of open fractures of the extremities is almost universal in all high-income countries, where benefits are assumed to outweigh potential risks. In the USA, a 100% compliance level is one of many required criteria for hospital re-credentialing by the Joint Committee for Accreditation of Healthcare Organisations (JCAHO). In many lower-income countries antibiotics may not be used routinely for various reasons: costs, lack of knowledge, low levels of suspicion of infection or poor case-recognition from first-line health care workers, availability, accessibility, and use of traditional or alternative health care. In some of these countries, the use of antibiotics for open fractures is delayed until the patient is seen in the secondary or even the tertiary care centres. This delay often exceeds the accepted "golden period" for treatment of six to eight hours used in high income countries. Since an open fracture is by definition contaminated, the use of antibiotics is therapeutic, not prophylactic, and aims at preventing subsequent infectious problems such as cellulitis, myositis, acute or chronic osteomyelitis (bone infection), infected non-unions, recurrent abscesses, chronic drainage with fistula formation, and their associated impairment and disability.</P>
<P>A related systematic review (<LINK REF="REF-Gillespie-2001" TYPE="REFERENCE">Gillespie 2001</LINK>) concluded that antibiotic prophylaxis should be offered to those undergoing surgical treatment of closed hip and other long bone fractures. Our purpose is to review the evidence for use of antibiotics in the treatment of open fractures of the extremities.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-08-04 22:42:01 +1200" MODIFIED_BY="Helen HG Handoll">
<P>To review the evidence for the effectiveness of antibiotics in the initial treatment of open fractures of the limbs.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-08-07 15:28:19 +1200" MODIFIED_BY="Lesley ">
<SELECTION_CRITERIA MODIFIED="2009-08-04 22:42:54 +1200" MODIFIED_BY="Helen HG Handoll">
<CRIT_STUDIES>
<P>Randomised and quasi-randomised (e.g. date of birth, alternation) controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People of any age with open fractures of the limbs.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Antibiotic administered before or at the time of primary treatment of the open fracture compared with placebo or no antibiotic. Trials comparing different antibiotics, different antibiotic dosages, route of administration or differences in timing or duration of administration were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-08-04 22:42:54 +1200" MODIFIED_BY="Helen HG Handoll">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<UL>
<LI>early wound infection (as defined in individual study reports)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>chronic wound discharge</LI>
<LI>acute or chronic osteomyelitis</LI>
<LI>delayed union or non-union</LI>
<LI>amputation</LI>
<LI>death</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-08-07 15:28:19 +1200" MODIFIED_BY="Lesley ">
<ELECTRONIC_SEARCHES MODIFIED="2009-08-07 15:28:19 +1200" MODIFIED_BY="Lesley ">
<P>We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (26 July 2009), the Cochrane Central Register of Controlled Trials/Clinical Trials (<I>The Cochrane Library</I> 2009, Issue 3), MEDLINE (1950 to July Week 3 2009), EMBASE (1980 to 2009 Week 30), <A HREF="http://bases.bvs.br/public/scripts/php/page_show_main.php?home=true&amp;lang=en&amp;form=simple#">Latin American and Caribbean Literature on the Health Sciences (LILACS)</A> (1982 to July 2009), and International Pharmaceutical Abstracts (1970 to July 2009).</P>
<P>The search strategy for MEDLINE combined a subject-specific section with the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE (sensitivity-maximizing version) (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>), and was modified for use in other databases (<I>see</I> <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). The MEDLINE search strategy for the previous version is shown in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>We searched the <A HREF="http://apps.who.int/trialsearch/Default.aspx">WHO International Clinical Trials Registry Platform</A> (July 2009) for ongoing trials.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-07-22 02:36:51 +1200" MODIFIED_BY="Lindsey Elstub">
<P>Proceedings of meetings of the American Academy of Orthopaedic Surgeons (1980 to 2001), the Orthopaedic Trauma Association (1990 to 2001) and the Société Internationale de Chirurgie Orthopedique et Traumatologique (1980 to 2001) were handsearched. We also searched reference lists of articles and contacted published researchers in the field.</P>
<P>No language restriction was applied.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-08-04 23:28:12 +1200" MODIFIED_BY="Helen HG Handoll">
<STUDY_SELECTION MODIFIED="2009-03-26 05:31:54 +1300" MODIFIED_BY="Lindsey Elstub">
<P>Two reviewers independently screened each record for eligibility by initially examining titles, abstracts and key words. Reports identified by either reviewer were retrieved. We searched the reference lists of relevant trials and reviews in which the largest number of eligible trials had been published. We contacted the authors of eligible trials and reviews to ask about unpublished trials. Reports of potentially eligible trials were obtained and two reviewers independently assessed each one for eligibility.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-03-26 05:33:19 +1300" MODIFIED_BY="Lindsey Elstub">
<P>Two reviewers independently extracted data from included reports using a standard pro forma. Data were extracted on the type of participants, the type of antibiotic used, the number randomised to intervention or control groups, the quality of allocation concealment, and the outcome measures stated in the protocol. We wrote to the authors of reports if relevant information was missing. Trials in which we could not confirm that random or quasi-random allocation had been used to allocate participants were excluded.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-08-04 23:28:12 +1200" MODIFIED_BY="Helen HG Handoll">
<P>Methodological quality for each study was independently assessed by two reviewers using a schedule derived from the former generic evaluation tool developed by the Cochrane Bone, Joint and Muscle Trauma Group (<I>see</I> <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), from which a risk of bias assessment was derived. Disagreements were resolved by consensus. The scores for individual items were designed to give readers a general impression of trial quality and were not used in any quantitative manner.</P>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Data synthesis</I>
</HEADING>
<P>For each intervention, we estimated the pooled risk ratio in a fixed-effect model. We calculated 95% confidence intervals for each outcome. Selection bias was assessed using Egger's weighted regression method and Begg's rank correlation test and funnel plot. Heterogeneity was assessed using visual inspection of overlap in the forest plot and consideration of the Chi² test and I² statistic. We planned three subgroup analyses exploring whether the effect differed between placebo-controlled and no-placebo studies, whether the effect of antimicrobials differed depending on the location of the fracture (specifically comparing use in phalangeal fractures in the hand with use in fractures of major limb bones), and whether the timing of antibiotic administration was a critical factor.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-08-07 02:57:57 +1200" MODIFIED_BY="Lindsey Elstub">
<STUDY_DESCRIPTION MODIFIED="2009-08-04 23:11:09 +1200" MODIFIED_BY="Helen HG Handoll">
<P>The updated search strategy identified 13 trials in which the use of any antibiotics for open fractures of the limbs was compared with placebo or no antibiotics. Five studies were excluded (<I>see</I> <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>) either because there was no randomisation (two studies), patients were randomised after an initial dose of antibiotics (one), or it was impossible to disaggregate data on open fractures and soft tissue injuries only (two). The remaining eight studies were included and are described in detail in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>There were three randomised double-blinded trials (<LINK REF="STD-Bergman-1982" TYPE="STUDY">Bergman 1982</LINK>; <LINK REF="STD-Braun-1987" TYPE="STUDY">Braun 1987</LINK>; <LINK REF="STD-Stevenson-2003" TYPE="STUDY">Stevenson 2003</LINK>), three quasi-randomised trials (<LINK REF="STD-Rojczyk-1983" TYPE="STUDY">Rojczyk 1983</LINK>; <LINK REF="STD-Dickey-1989" TYPE="STUDY">Dickey 1989</LINK>; <LINK REF="STD-Suprock-1990" TYPE="STUDY">Suprock 1990</LINK>), and two trials where the randomisation methods were unclear (<LINK REF="STD-Patzakis-1974" TYPE="STUDY">Patzakis 1974</LINK>; <LINK REF="STD-Sloan-1987" TYPE="STUDY">Sloan 1987</LINK>).</P>
<P>Three studies were limited to open fractures of fingers (<LINK REF="STD-Sloan-1987" TYPE="STUDY">Sloan 1987</LINK>; <LINK REF="STD-Stevenson-2003" TYPE="STUDY">Stevenson 2003</LINK>; <LINK REF="STD-Suprock-1990" TYPE="STUDY">Suprock 1990</LINK>), while four excluded hand and finger fractures (<LINK REF="STD-Bergman-1982" TYPE="STUDY">Bergman 1982</LINK>; <LINK REF="STD-Braun-1987" TYPE="STUDY">Braun 1987</LINK>; <LINK REF="STD-Dickey-1989" TYPE="STUDY">Dickey 1989</LINK>; <LINK REF="STD-Rojczyk-1983" TYPE="STUDY">Rojczyk 1983</LINK>). <LINK REF="STD-Patzakis-1974" TYPE="STUDY">Patzakis 1974</LINK> included all fractures of the extremities. Four studies included only patients in the ill-defined 'adult age group' (<LINK REF="STD-Bergman-1982" TYPE="STUDY">Bergman 1982</LINK>; <LINK REF="STD-Braun-1987" TYPE="STUDY">Braun 1987</LINK>; <LINK REF="STD-Dickey-1989" TYPE="STUDY">Dickey 1989</LINK>; <LINK REF="STD-Sloan-1987" TYPE="STUDY">Sloan 1987</LINK>). Two studies included patients of all ages (<LINK REF="STD-Patzakis-1974" TYPE="STUDY">Patzakis 1974</LINK>; <LINK REF="STD-Rojczyk-1983" TYPE="STUDY">Rojczyk 1983</LINK>) and one study did not mention age (<LINK REF="STD-Suprock-1990" TYPE="STUDY">Suprock 1990</LINK>). Participants in <LINK REF="STD-Stevenson-2003" TYPE="STUDY">Stevenson 2003</LINK> were aged over 16 years.</P>
<P>Four studies used a placebo (<LINK REF="STD-Bergman-1982" TYPE="STUDY">Bergman 1982</LINK>; <LINK REF="STD-Braun-1987" TYPE="STUDY">Braun 1987</LINK>; <LINK REF="STD-Sloan-1987" TYPE="STUDY">Sloan 1987</LINK>; <LINK REF="STD-Stevenson-2003" TYPE="STUDY">Stevenson 2003</LINK>). Antibiotic regimens differed but all employed penicillin derivatives or first generation cephalosporins, active against gram-positive organisms: Penicillin/streptomycin and cephalothin (<LINK REF="STD-Patzakis-1974" TYPE="STUDY">Patzakis 1974</LINK>); penicillin and dicloxacillin (<LINK REF="STD-Bergman-1982" TYPE="STUDY">Bergman 1982</LINK>); cloxacillin (<LINK REF="STD-Braun-1987" TYPE="STUDY">Braun 1987</LINK>); flucloxacillin (<LINK REF="STD-Stevenson-2003" TYPE="STUDY">Stevenson 2003</LINK>); cefazolin (<LINK REF="STD-Dickey-1989" TYPE="STUDY">Dickey 1989</LINK>; <LINK REF="STD-Rojczyk-1983" TYPE="STUDY">Rojczyk 1983</LINK>); first generation cephalosporin, dicloxacillin or erythromycin (<LINK REF="STD-Suprock-1990" TYPE="STUDY">Suprock 1990</LINK>); or cephradine (<LINK REF="STD-Sloan-1987" TYPE="STUDY">Sloan 1987</LINK>). There were also differences in the duration and route of administration of treatment.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-07-30 01:36:25 +1200" MODIFIED_BY="Lindsey Elstub">
<P>The risk of bias in the included studies varied (<I>see</I> <LINK REF="FIG-01" TYPE="FIGURE">Figure 1 </LINK>and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Only <LINK REF="STD-Stevenson-2003" TYPE="STUDY">Stevenson 2003</LINK> provided information on sequence generation for randomisation. Concealment of allocation and blinding were judged adequate in three studies (<LINK REF="STD-Bergman-1982" TYPE="STUDY">Bergman 1982</LINK>; <LINK REF="STD-Braun-1987" TYPE="STUDY">Braun 1987</LINK>; <LINK REF="STD-Stevenson-2003" TYPE="STUDY">Stevenson 2003</LINK>). Hence, these three trials were considered to be at a lower risk of bias than the other five trials. The trialists' reported definitions of outcome varied, as did length of follow-up periods. Wound infection required microbiological confirmation in five studies (<LINK REF="STD-Bergman-1982" TYPE="STUDY">Bergman 1982</LINK>; <LINK REF="STD-Braun-1987" TYPE="STUDY">Braun 1987</LINK>; <LINK REF="STD-Patzakis-1974" TYPE="STUDY">Patzakis 1974</LINK>; <LINK REF="STD-Rojczyk-1983" TYPE="STUDY">Rojczyk 1983</LINK>; <LINK REF="STD-Sloan-1987" TYPE="STUDY">Sloan 1987</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-08-07 02:57:57 +1200" MODIFIED_BY="Lindsey Elstub">
<P>Although there was no uniform definition of the primary outcome measure, we considered that those measures used in each study were clinically sufficiently consistent to permit pooling. The data did not permit the analysis of secondary outcomes (osteomyelitis, chronic drainage, infected non-union, amputation for infection, or infection-related death).The antibiotic regimens varied significantly in terms of agents used and duration, but we found each regimen likely to be effective at the time of the study against the gram-positive organisms usually associated with early infection in open fractures.</P>
<P>The data from 1106 participants in the eight studies were pooled (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), subgrouped by lower and higher risk of bias (<I>see</I> <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). In the overall analysis, antibiotics significantly reduced the incidence of wound infection (risk ratio (RR) 0.43, 95% confidence interval (CI) 0.29 to 0.65). The absolute risk of wound infection was 0.11 (53/461) in the controls (no antibiotic) and 0.05 (33/645) in those receiving any antibiotics, giving an absolute risk reduction of 0.07 (95% CI 0.03 to 0.10) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). In the subgroup analysis, the lower risk of bias group had an absolute risk of wound infection of 0.13 (22/169) for the controls and 0.04 (9/201) for those receiving antibiotics (risk difference -0.09 (95% CI -0.03 to -0.15), while the no-placebo group had an absolute risk of 0.11 (31/292) for the controls and 0.05 (24/444) for those receiving antibiotics (risk difference -0.05 (95%CI -0.01 to -0.10). The difference between these subgroups was not statistically significant.</P>
<P>Subgroup analysis (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) explored the importance of fracture location and found that in open finger fractures, there was no evidence of significant benefit from antibiotics (3 trials, 367 participants; RR 0.56, 95% CI 0.26 to 1.23). In trials which did not include open finger fractures, antibiotics significantly reduced early infection (4 trials, 472 participants, RR 0.37, 95% CI 0.21 to 0.68). However, the difference between the two groups was not statistically significant.</P>
<P>Subgroup analysis based on the timing of antibiotic administration was not possible as the necessary data were not available.<BR/>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-08-04 23:35:19 +1200" MODIFIED_BY="Helen HG Handoll">
<SUMMARY_OF_RESULTS MODIFIED="2009-03-26 05:57:57 +1300" MODIFIED_BY="Lindsey Elstub">
<P>Despite the risk of bias and relative lack of power of most studies, meta-analysis supports the effectiveness of antibiotics active against gram-positive organisms in reducing the incidence of early infection when administered before or at the time of primary treatment of an open limb fracture, at least in the short term. All authors agree that antibiotic therapy is an adjunct to, not a replacement for, a comprehensive open fracture management protocol that includes early lavage, surgical debridement, fracture stabilisation when appropriate, and bone grafting and wound coverage if necessary. Subgroup analysis indicates that antibiotic prophylaxis administered to people with open finger fractures may not reduce the incidence of early infection, but the difference between subgroups is not significant. We did not include trials comparing one antimicrobial agent against another, or comparing single dose or short course administration with longer periods of prophylaxis.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-08-04 23:26:05 +1200" MODIFIED_BY="Helen HG Handoll">
<P>Although the number of included studies is small, and the review has a number of limitations in overall completeness and applicability, it establishes with some confidence the effectiveness of antibiotic prophylaxis directed at gram-positive organisms in reducing early infection after open fracture in the extremities.</P>
<P>We feel confident that our search strategy was thorough and comprehensive, although limited to Europe and the Americas. We did not apply any language restriction, but we were unable to search Chinese or Japanese databases. We cannot rule out the possibility of publication bias.</P>
<P>The limitations in completeness and applicability arise from the limited scope of the included studies as much as from their quality. They include:</P>
<P>1. Data from the included studies does not permit the analysis of a number of longer-term outcomes, such as chronic osteomyelitis, infected non-union, amputation for infection, or infection-related death.</P>
<P>2. Although raising the hypothesis that antibiotics may possibly not be effective in the case of relatively low energy injuries (phalangeal fractures in the finger), the available data did not allow exploration of whether effectiveness differs with the severity or grade of the open wound.</P>
<P>3. Available data did not allow exploration of the optimal duration of prophylaxis in respect of either effectiveness or adverse effects.</P>
<P>4. This review does not address some of the important issues faced in the management of major trauma in the first decade of the 21st century, in which the treatment of infection caused by antimicrobial resistant organisms, both gram-positive and gram-negative, plays an important part. The included studies did not address the question of whether antibiotic prophylaxis contributes to the development of antimicrobial resistance, as a number of studies in the last decade have suggested. Nor did they address the question of whether prophylaxis should take into account the increasing incidence of multiple antibiotic resistance amongst gram-positive organisms, particularly Staphylococcus aureus. Nor did they provide useful data on the incidence of hypersensitivity reactions to the antibiotic agents used.</P>
<P>5.The extent to which results from studies carried out in developed countries, where antibiotics are part of a comprehensive open fracture management protocol, are applicable to developing countries remains debatable. We found no studies from developing countries comparing antibiotics as the main, or even the only initial treatment of open fractures of the limbs, to placebo or no treatment. Nevertheless, it seems reasonable to assume that, at least to some extent, the findings of this review would apply to low-resource settings. If good data on open fracture prevalence and incidence were available for a given population, it could be possible to estimate the morbidity burden that might be avoidable. An economic analysis taking the local context into account could then evaluate the costs and benefits.</P>
<P>Although it seems somewhat unlikely that further placebo-controlled trials of antibiotic prophylaxis for open fracture management could be justified, future studies could certainly address longer-term outcomes and duration of prophylaxis (probably single dose versus a longer but restricted regimen). <LINK REF="REF-Dellinger-1991" TYPE="REFERENCE">Dellinger 1991</LINK> listed recommendations for the conduct and reporting of clinical trials on the management of open fractures which should improve both study quality and applicability of data.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-08-04 23:34:08 +1200" MODIFIED_BY="Helen HG Handoll">
<P>Only three placebo-controlled included studies (<LINK REF="STD-Bergman-1982" TYPE="STUDY">Bergman 1982</LINK>; <LINK REF="STD-Braun-1987" TYPE="STUDY">Braun 1987</LINK>; <LINK REF="STD-Stevenson-2003" TYPE="STUDY">Stevenson 2003</LINK> ) were judged to have both adequate allocation concealment and blinding. The subgroup analysis which shows a larger effect in these studies with lower risk of bias than in those with higher risk of bias is reassuring. Another potential weakness comes from the relatively short periods of follow-up in most studies, although it is impossible to estimate in which direction this would bias the results. On the other hand, very few patients were lost to follow-up, and all data analyses appear to have been intention-to-treat analyses.</P>
<P>The precision of the results of this systematic review may be decreased by the relatively small numbers of included studies, and participants. This is unlikely to change in the future. It is doubtful whether further trials using placebo or no antibiotics will be justifiable, as the use of antibiotics has been part of the standard care of open fractures of the extremities since the mid 1970s, despite some controversy about its use in open fractures of the fingers.</P>
</QUALITY_OF_EVIDENCE>
<AGREEMENT MODIFIED="2009-08-04 23:35:19 +1200" MODIFIED_BY="Helen HG Handoll">
<P>The Eastern Association for the Surgery of Trauma (<LINK REF="REF-EAST-2000" TYPE="REFERENCE">EAST 2000</LINK>) has published a literature review leading to "practice management guidelines for prophylactic antibiotic use in open fractures" which is in agreement with the findings of this review. More recently, <LINK REF="REF-Hauser-2006" TYPE="REFERENCE">Hauser 2006</LINK>, although noting that "current antibiotic management of open fractures is based on a small number of studies that generally are more than 30 years old and do not reflect current management priorities in trauma and critical care", concluded, as this review does, that a short course of an agent effective against gram-positive organisms such as a first-generation cephalosporin "begun as soon as possible after injury, significantly lowers the risk of infection when used in combination with prompt, modern orthopedic fracture wound management".</P>
<P>A recent systematic review and economic analysis (<LINK REF="REF-Cranny-2008" TYPE="REFERENCE">Cranny 2008</LINK>) has addressed the issue of whether the choice of agent for routine antibiotic prophylaxis for surgery should take account of multiple antibiotic resistance in <I>Staphylococcus aureus </I>(MRSA)<I> </I>by a switch from non-glycopeptide to glycopeptide prophylaxis. It concluded that "There is insufficient evidence to determine whether there is a threshold prevalence of MRSA at which switching from non-glycopeptide to glycopeptide antibiotic prophylaxis might be clinically effective and cost-effective. Future research needs to address the complexities of decision-making relating to the prevention of MRSA and infection control in general. Research including evidence synthesis and decision modelling comparing a full range of interventions for infection control, which extends to other infections, not just MRSA, is needed."</P>
<P>The problem of adverse effects of antibiotic prophylaxis, in particular hypersensitivity reactions, the development of antibiotic associated diarrhoea, and the development of antibiotic resistance to which this review was unable to contribute any evidence has recently been reviewed in a contemporary Practice Guideline on antibiotic prophylaxis in surgery (<LINK REF="REF-SIGN-2008" TYPE="REFERENCE">SIGN 2008</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-08-05 00:12:36 +1200" MODIFIED_BY="Helen HG Handoll">
<IMPLICATIONS_PRACTICE MODIFIED="2009-08-05 00:12:36 +1200" MODIFIED_BY="Helen HG Handoll">
<P>The use of a prophylactic antibiotic regimen effective against gram-positive organisms (for example a narrow spectrum beta-lactam agent such as dicloxacillin or flucloxacillin, or a first generation cephalosporin), begun as soon as possible after injury, significantly lowers the risk of early infection after an open fracture when used in combination with good wound management.</P>
<P>Although no relevant data could be provided by this review, health professionals and people at risk should ensure their awareness of the adverse effects of antibiotic prophylaxis.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-03-22 13:23:52 +1300" MODIFIED_BY="[Empty name]">
<P>1. Further placebo controlled trials to evaluate the effectiveness of antibiotics for open fractures of the limbs proximal to the phalanges are unwarranted. There may be a case for further evaluation of the effectiveness of antibiotic prophylaxis in open finger fractures. </P>
<P>2. For those populations for which antibiotics are not universally used in the management of open fractures, reliable epidemiological data on the incidence and prevalence of open fractures, prevalence of antibiotic utilisation, and incidence and prevalence of infectious complications would allow quantifying the avoidable burden associated with this problem.</P>
<P>3. Both in these low-resource settings, where management of open fractures is inconsistent, and in settings where antibiotic administration is routine, there may be justification for further studies comparing the benefits of single versus multiple doses of antibiotics, and which antibiotic by which route.</P>
<P>4. Economic analysis would then allow the most cost-effective intervention regimen to be determined, and to value the costs and benefits associated with burden reduction.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-03-22 13:25:15 +1300" MODIFIED_BY="[Empty name]">
<P>The authors would like to acknowledge the following for their help in the preparation of the original review, and this update: Ms Leeann Morton, Mrs Lesley Gillespie and Ms Frances Bunn. We would also like to thank the following for their useful comments during the editorial review process: Professor John Stothard, Professor Marc Swiontkowski, Professor Rajan Madhok, Associate Professor Peter Herbison and Dr Janet Wale.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-10-29 17:00:12 +1300" MODIFIED_BY="[Empty name]">
<P>All reviewers contributed to the protocol development and the editing of the review. One reviewer (RG) executed the search strategy. All reviewers independently assessed trial quality and extracted data. WJG contributed to the drafting of this update. Richard Gosselin is the guarantor of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-08-07 15:46:01 +1200" MODIFIED_BY="Lesley ">
<STUDIES MODIFIED="2009-08-07 15:31:19 +1200" MODIFIED_BY="Lesley ">
<INCLUDED_STUDIES MODIFIED="2009-08-07 15:30:26 +1200" MODIFIED_BY="Lesley ">
<STUDY DATA_SOURCE="PUB" ID="STD-Bergman-1982" NAME="Bergman 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergman BR</AU>
<TI>Antibiotic prophylaxis in open and closed fractures: a controlled clinical trial</TI>
<SO>Acta Orthopaedica Scandinavica</SO>
<YR>1982</YR>
<VL>53</VL>
<NO>1</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braun-1987" MODIFIED="2009-08-07 15:30:26 +1200" MODIFIED_BY="Lesley " NAME="Braun 1987" YEAR="">
<REFERENCE MODIFIED="2009-08-07 15:30:26 +1200" MODIFIED_BY="Lesley " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun R, Enzler MA, Rittmann WW</AU>
<TI>A double-blind clinical trial of prophylactic cloxacillin in open fractures</TI>
<SO>Journal of Orthopaedic Trauma</SO>
<YR>1987</YR>
<VL>1</VL>
<NO>1</NO>
<PG>12-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dickey-1989" NAME="Dickey 1989" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dickey RL, Barnes BC, Kearns RJ, Tullos HS</AU>
<TI>Efficacy of antibiotics in low-velocity gunshot fractures</TI>
<SO>Journal of Orthopaedic Trauma</SO>
<YR>1989</YR>
<VL>3</VL>
<NO>1</NO>
<PG>6-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patzakis-1974" NAME="Patzakis 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Patzakis MJ, Harvey JP, Ivler D</AU>
<TI>The role of antibiotics in the management of open fractures</TI>
<SO>Journal of Bone and Joint Surgery. American Volume</SO>
<YR>1974</YR>
<VL>56</VL>
<NO>3</NO>
<PG>532-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Patzakis MJ, Ivler D. Antibiotic and bacteriologic considerations in open fractures. Southern Medical Journal 1977; 70 Suppl 1:46-48.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patzakis MJ, Ivler D</AU>
<TI>Antibiotic and bacteriologic considerations in open fractures</TI>
<SO>Southern Medical Journal</SO>
<YR>1977</YR>
<VL>70 Suppl 1</VL>
<PG>46-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rojczyk-1983" MODIFIED="2009-03-31 04:45:54 +1300" MODIFIED_BY="[Empty name]" NAME="Rojczyk 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-03-31 04:45:54 +1300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rojczyk M, Malottke R. [The effect of antibiotic prophylaxis in the treatment of open fractures]. [German]. Hefte zur Unfallheilkunde 1979; 138:355-357.&lt;/p&gt;" NOTES_MODIFIED="2009-03-31 04:45:54 +1300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rojczyk M, Malottke R</AU>
<TI>The effect of antibiotic prophylaxis in the treatment of open fractures</TI>
<TO>Untersuchungen uber den Einfluss einer Antibiotica-prophylaxe bei der Behandlung offener Frakturen</TO>
<SO>Hefte zur Unfallheilkunde</SO>
<YR>1979</YR>
<VL>138</VL>
<PG>355-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Rojczyk M. Antibiotica doses in open fractures. Hefte zur Unfallheilkunde 1980; 148:861-862.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rojczyk M</AU>
<TI>Antibiotic doses in open fractures</TI>
<SO>Hefte zur Unfallheilkunde</SO>
<YR>1980</YR>
<VL>148</VL>
<PG>861-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rojczyk M</AU>
<TI>Treatment results in open fractures, aspects of antibiotic therapy</TI>
<TO>Behandlungsergebnisse bei offenen frakturen, aspekte der antibiotikatherapie</TO>
<SO>Hefte zur Unfallheilkunde</SO>
<YR>1983</YR>
<VL>162</VL>
<PG>33-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sloan-1987" MODIFIED="2009-03-31 04:48:28 +1300" MODIFIED_BY="[Empty name]" NAME="Sloan 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-03-31 04:48:28 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sloan JP, Dove AF, Maheson M, Cope AN, Welsh KR</AU>
<TI>Antibiotics in open fractures of the distal phalanx?</TI>
<SO>Journal of Hand Surgery - British Volume</SO>
<YR>1987</YR>
<VL>12</VL>
<NO>1</NO>
<PG>123-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevenson-2003" MODIFIED="2009-07-29 11:18:41 +1200" MODIFIED_BY="Lesley " NAME="Stevenson 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-29 11:18:41 +1200" MODIFIED_BY="Lesley " NOTES="&lt;p&gt;Stevenson J. McNaughton G. Riley J. The use of prophylactic flucloxacillin in treatment of open fractures of the distal phalanx within an accident and emergency department: a double-blind randomized placebo-controlled trial. [Clinical Trial. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] Journal of Hand Surgery - British Volume. 28(5):388-94, 2003 Oct.&lt;br&gt;UI: 12954243&lt;/p&gt;" NOTES_MODIFIED="2009-07-29 11:18:41 +1200" NOTES_MODIFIED_BY="Lesley " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stevenson J, McNaughton G, Riley J</AU>
<TI>The use of prophylactic flucloxacillin in treatment of open fractures of the distal phalanx within an accident and emergency department: a double-blind randomised placebo-controlled trial</TI>
<SO>Journal of Hand Surgery - British Volume</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>5</NO>
<PG>388-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suprock-1990" MODIFIED="2009-03-31 04:48:44 +1300" MODIFIED_BY="[Empty name]" NAME="Suprock 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-03-31 04:48:44 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suprock MD, Hood JM, Lubahn JD</AU>
<TI>Role of antibiotics in open fractures of the finger</TI>
<SO>Journal of Hand Surgery - American Volume</SO>
<YR>1990</YR>
<VL>15</VL>
<NO>5</NO>
<PG>761-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-08-07 15:31:19 +1200" MODIFIED_BY="Lesley ">
<STUDY DATA_SOURCE="PUB" ID="STD-Almanza-1999" NAME="Almanza 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;no randomisation&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Almanza AJ, Reyes AG, Diaz RR</AU>
<TI>Antibiotic treatment in open fractures</TI>
<TO>Tratamiento antimicrobiano en las fracturas expuestas</TO>
<SO>Revisa Mexicana Ortopedica Traumatologia</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>5</NO>
<PG>470-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altergott-2008" MODIFIED="2009-07-29 11:41:38 +1200" MODIFIED_BY="Lesley " NAME="Altergott 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-29 11:41:38 +1200" MODIFIED_BY="Lesley " NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Altergott C. Garcia FJ. Nager AL. Pediatric fingertip injuries: do prophylactic antibiotics alter infection rates?. [Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural] Pediatric Emergency Care. 24(3):148-52, 2008 Mar.&lt;br&gt;UI: 18347491&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2009-07-29 11:41:38 +1200" NOTES_MODIFIED_BY="Lesley " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altergott C, Garcia FJ, Nager AL</AU>
<TI>Pediatric fingertip injuries: do prophylactic antibiotics alter infection rates?</TI>
<SO>Pediatric Emergency Care</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>3</NO>
<PG>148-52</PG>
<IDENTIFIERS MODIFIED="2009-07-29 11:41:38 +1200" MODIFIED_BY="Lesley ">
<IDENTIFIER MODIFIED="2009-07-29 11:41:38 +1200" MODIFIED_BY="Lesley " TYPE="MEDLINE" VALUE="18347491"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cutler-1944" NAME="Cutler 1944" YEAR="1944">
<REFERENCE NOTES="&lt;p&gt;not randomised&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cutler EC, Morton PC, Sandusky WR</AU>
<TI>Observations on the prophylactic use of penicillin in the wounds of aerial warfare</TI>
<SO>British Journal of Surgery</SO>
<YR>1944</YR>
<VL>32</VL>
<PG>207-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1986" MODIFIED="2009-08-07 15:31:19 +1200" MODIFIED_BY="Lesley " NAME="Miller 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-08-07 15:31:19 +1200" MODIFIED_BY="Lesley " NOTES="&lt;p&gt;all patients received first one dose of antibiotics, and were then randomised to more or no more abs&lt;/p&gt;" NOTES_MODIFIED="2009-08-07 15:31:19 +1200" NOTES_MODIFIED_BY="Lesley " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller SD, Bray RC, Hughes GNF</AU>
<TI>Antibiotics in open fractures: a prospective randomised, double-blind study of wound infection [abstract]</TI>
<SO>Journal of Bone and Joint Surgery - British Volume</SO>
<YR>1986</YR>
<VL>68</VL>
<NO>5</NO>
<PG>850</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peacock-1988" MODIFIED="2009-03-31 04:50:56 +1300" MODIFIED_BY="[Empty name]" NAME="Peacock 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-03-31 04:50:56 +1300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;does not separate fractures from soft tissue injuries&lt;/p&gt;" NOTES_MODIFIED="2009-03-31 04:50:56 +1300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peacock KC, Hanna DP, Kirkpatrick K, Breidenbach WC, Lister GD, Firrell J</AU>
<TI>Efficacy of perioperative cefamandole with postoperative cephalexin in the primary outpatient treatment of open wounds of the hand</TI>
<SO>Journal of Hand Surgery - American Volume</SO>
<YR>1988</YR>
<VL>13</VL>
<NO>6</NO>
<PG>960-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-08-07 15:46:01 +1200" MODIFIED_BY="Lesley ">
<ADDITIONAL_REFERENCES MODIFIED="2009-08-07 15:46:01 +1200" MODIFIED_BY="Lesley ">
<REFERENCE ID="REF-Cranny-2008" MODIFIED="2009-03-31 04:34:25 +1300" MODIFIED_BY="[Empty name]" NAME="Cranny 2008" NOTES="&lt;p&gt;Cranny G. Elliott R. Weatherly H. Chambers D. Hawkins N. Myers L. Sculpher M. Eastwood A. A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery. [Review] [158 refs] [Journal Article. Review] Health Technology Assessment (Winchester, England). 12(1):iii-iv, xi-xii, 1-147, 2008 Jan.&lt;br&gt;UI: 18093447&lt;/p&gt;" NOTES_MODIFIED="2009-03-31 04:34:25 +1300" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Cranny G, Elliott R, Weatherly H, Chambers D, Hawkins N, Myers L, et al</AU>
<TI>A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery</TI>
<SO>Health Technology Assessment</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>1</NO>
<PG>i-168</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dellinger-1991" MODIFIED="2009-03-31 04:37:18 +1300" MODIFIED_BY="[Empty name]" NAME="Dellinger 1991" NOTES="&lt;p&gt;Dellinger EP. Antibiotic prophylaxis in trauma: penetrating abdominal injuries and open fractures. [Review] [66 refs] [Clinical Trial. Journal Article. Review] Reviews of Infectious Diseases. 13 Suppl 10:S847-57, 1991 Sep-Oct.&lt;br&gt;UI: 1754794&lt;/p&gt;" NOTES_MODIFIED="2009-03-31 04:37:18 +1300" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Dellinger EP</AU>
<TI>Antibiotic prophylaxis in trauma: penetrating abdominal injuries and open fractures</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>Suppl 10</NO>
<PG>S847-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EAST-2000" MODIFIED="2009-08-07 15:45:56 +1200" MODIFIED_BY="Lesley " NAME="EAST 2000" TYPE="OTHER">
<AU>Luchette FA, Bone LB, Born CT, DeLong WG, Hoff WS, Mullins D, et al</AU>
<TI>EAST practice management guidelines work group: Practice management guidelines for prophylactic antibiotic use in open fractures</TI>
<SO>Eastern Association for the Surgery of Trauma www.east.org/tgp/openfrac.pdf</SO>
<YR>(accessed 01 March 2002)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gillespie-2001" MODIFIED="2009-03-31 05:27:08 +1300" MODIFIED_BY="[Empty name]" NAME="Gillespie 2001" NOTES="&lt;p&gt;Gillespie WJ, Walenkamp G. Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures. &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2001, Issue 1. Art. No.: CD000244. DOI: 10.1002/14651858.CD000244.&lt;/p&gt;" NOTES_MODIFIED="2009-03-31 05:27:08 +1300" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Gillespie WJ, Walenkamp G</AU>
<TI>Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-03-31 05:26:04 +1300" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-31 05:26:04 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000244"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hauser-2006" MODIFIED="2009-03-31 04:42:20 +1300" MODIFIED_BY="[Empty name]" NAME="Hauser 2006" NOTES="&lt;p&gt;Hauser C.J., Adams Jr. C.A., Eachempati S.R. Prophylactic antibiotic use in open fractures: An evidence-based guideline. [Journal: Review] Surgical Infections. 7(4)(pp 379-405), 2006. Date of Publication: Aug 2006.&lt;br&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-03-31 04:42:20 +1300" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Hauser CJ, Adams CA Jr, Eachempati SR</AU>
<TI>Prophylactic antibiotic use in open fractures: An evidence-based guideline</TI>
<SO>Surgical Infections</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>4</NO>
<PG>379-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2009-08-07 15:46:01 +1200" MODIFIED_BY="Lesley " NAME="Lefebvre 2008" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies, Box 6.4.c</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SIGN-2008" MODIFIED="2009-07-29 11:58:42 +1200" MODIFIED_BY="Lesley " NAME="SIGN 2008" TYPE="OTHER">
<AU>Scottish Intercollegiate Guidelines Network (SIGN)</AU>
<TI>Antibiotic prophylaxis in surgery. Edinburgh: SIGN, 2008</TI>
<SO>www.sign.ac.uk/pdf/sign104.pdf</SO>
<YR>(accessed 26 July 2009)</YR>
<IDENTIFIERS MODIFIED="2009-07-29 11:58:42 +1200" MODIFIED_BY="Lesley ">
<IDENTIFIER MODIFIED="2009-07-29 11:58:42 +1200" MODIFIED_BY="Lesley " TYPE="OTHER" VALUE="ISBN 978 1 905813 34 6"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-07-29 12:19:35 +1200" MODIFIED_BY="Lesley ">
<REFERENCE ID="REF-Gosselin-2004" MODIFIED="2009-07-29 12:19:35 +1200" MODIFIED_BY="Lesley " NAME="Gosselin 2004" TYPE="COCHRANE_REVIEW">
<AU>Gosselin RA, Roberts I, Gillespie WJ</AU>
<TI>Antibiotics for preventing infection in open limb fractures</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-07-29 12:19:35 +1200" MODIFIED_BY="Lesley ">
<IDENTIFIER MODIFIED="2009-07-29 12:19:35 +1200" MODIFIED_BY="Lesley " TYPE="DOI" VALUE="10.1002/14651858.CD003764.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-08-07 15:46:06 +1200" MODIFIED_BY="Lesley ">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-08-07 15:46:06 +1200" MODIFIED_BY="Lesley " SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-08-07 15:46:06 +1200" MODIFIED_BY="Lesley " STUDY_ID="STD-Bergman-1982">
<CHAR_METHODS MODIFIED="2009-07-25 01:40:08 +1200" MODIFIED_BY="Lindsey Elstub">
<P>RCT<BR/>Double-blinded<BR/>Placebo<BR/>Cultures for diagnosis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-07 03:06:10 +1200" MODIFIED_BY="Lindsey Elstub">
<P>Sweden<BR/>90 adults with open extremity fractures, excluding hand and finger fractures, recruited over 30 months<BR/>60 cases treated with dicloxacillin or benzyl penicillin<BR/>30 controls treated with placebo<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 23:37:06 +1200" MODIFIED_BY="Helen HG Handoll">
<P>1. Intervention: 2 g dicloxacillin: first dose given pre-operatively with infusions repeated every six hours for two days.<BR/>2. Intervention: 3 million units benzyl penicillin: first dose given pre-operatively with infusions repeated every six hours for two days.<BR/>3. Control: 100 ml saline: in the same dosing regimen as for the intervention groups.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-25 01:37:21 +1200" MODIFIED_BY="Lindsey Elstub">
<P>Early wound infection: a wound was considered infected when signs of inflammation were present, i.e. supra-fascial drainage and a positive bacterial culture.<BR/>Deep infection was defined as a subfascial process going down to the bone or osteosynthesis material.<BR/>Superficial thrombophlebitis was defined as a palpable fibrotic vessel or visible inflammation along the course of the vessel.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-07 15:46:06 +1200" MODIFIED_BY="Lesley ">
<P>F/U until wound healed or drainage</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-07 15:45:51 +1200" MODIFIED_BY="Lesley " STUDY_ID="STD-Braun-1987">
<CHAR_METHODS MODIFIED="2009-07-25 01:40:12 +1200" MODIFIED_BY="Lindsey Elstub">
<P>RCT<BR/>Double-blinded<BR/>Placebo<BR/>Cultures for diagnosis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-07 03:09:05 +1200" MODIFIED_BY="Lindsey Elstub">
<P>Switzerland<BR/>100 consecutive adults with open extremity fractures 13 excluded (hand fractures, skull fractures, colon injury, previous use of antibiotics)<BR/>87 participants:<BR/>43 cases treated with cloxacillin<BR/>44 controls treated with placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 22:26:13 +1200" MODIFIED_BY="Helen HG Handoll">
<P>1. Intervention: During the first four days, four 1 g doses of cloxacillin were administered intravenously. Thereafter, four 1.5 g doses of cloxacillin were given orally for six days.<BR/>2. Control: Indistinguishable placebo given in the same dosing regimen as for the intervention group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 23:37:52 +1200" MODIFIED_BY="Helen HG Handoll">
<P>Early wound infection: (up to 6 weeks). Wound swabs were taken at weekly intervals from the base of the wound and the surrounding skin.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-07 15:45:51 +1200" MODIFIED_BY="Lesley ">
<P>F/U up to 10 months<BR/>Cloxacillin group:<BR/>- 2 urticaria<BR/>- 3 Gastro-intestinal symptoms<BR/>- 1 phlebitis<BR/>Placebo group:<BR/>- 7 phlebitis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-07 15:45:50 +1200" MODIFIED_BY="Lesley " STUDY_ID="STD-Dickey-1989">
<CHAR_METHODS MODIFIED="2009-07-25 01:40:15 +1200" MODIFIED_BY="Lindsey Elstub">
<P>CCT quasi-randomised (alternate days)<BR/>No blinding<BR/>No placebo<BR/>No cultures<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-07 03:07:18 +1200" MODIFIED_BY="Lindsey Elstub">
<P>USA<BR/>96 adults with open extremity fractures, excluding hand and finger fractures, recruited over 20 months:<BR/>46 cases with treatment<BR/>50 controls without treatment<BR/>Results reported on 32 cases treated with cefazolin, 35 without treatment</P>
<P>Hand injuries excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 23:38:08 +1200" MODIFIED_BY="Helen HG Handoll">
<P>1. Intervention: One day of intravenous cefazolin, three 1 g doses given eight hourly.<BR/>2. Control: No antibiotics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Early wound infection: any wound complication including prolonged drainage, erythema, or any physical findings such as cellulitis, localised fluctuance or drainage.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-07 15:45:50 +1200" MODIFIED_BY="Lesley ">
<P>F/U until bony union<BR/>30% loss to F/U<BR/>low-velocity gunshot wounds only<BR/>case-definition?</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-07 15:45:50 +1200" MODIFIED_BY="Lesley " STUDY_ID="STD-Patzakis-1974">
<CHAR_METHODS MODIFIED="2009-07-25 01:40:20 +1200" MODIFIED_BY="Lindsey Elstub">
<P>RCT<BR/>No blinding<BR/>No placebo<BR/>Cultures for diagnosis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-07 03:07:25 +1200" MODIFIED_BY="Lindsey Elstub">
<P>USA<BR/>310 consecutive patients with open extremity fractures, including hand and finger fractures, recruited over 12 months<BR/>212 cases treated with penicillin and streptomycin, or cephalotin<BR/>98 controls without treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-05 00:14:00 +1200" MODIFIED_BY="Helen HG Handoll">
<P>1. Intervention: Adults received 10 million units benzyl penicillin per day in a continuous infusion and 0.5 g streptomycin intramuscularly every 12 hours. Children received 100,000 units of penicillin per kilogram of body weight per day in a continuous infusion and 7.5 mg of streptomycin per kilogram of body weight every 12 hours intramuscularly.<BR/>2. Intervention: Both adults and children received cephalothin, 100 mg per kilogram of body weight per day in divided dosage intravenously every six hours.<BR/>3. Control: No antibiotics.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Early wound infection: clinical signs and symptoms of wound infection present such as fever, erythema, tenderness, and wound drainage with either a positive gram stain or a positive culture. Either of the latter two had to be present before the wound was classified as infected.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-07 15:45:50 +1200" MODIFIED_BY="Lesley ">
<P>Length of F/U not specified.<BR/>If gunshot wounds excluded (none got an infection) infections in cases: 11 in 176<BR/>Infections in controls: 11 in 79</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-07 15:45:50 +1200" MODIFIED_BY="Lesley " STUDY_ID="STD-Rojczyk-1983">
<CHAR_METHODS MODIFIED="2009-07-25 01:40:24 +1200" MODIFIED_BY="Lindsey Elstub">
<P>CCT quasi-randomised (alternate days)<BR/>No blinding<BR/>No placebo<BR/>Cultures for diagnosis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-07 03:07:57 +1200" MODIFIED_BY="Lindsey Elstub">
<P>Germany<BR/>199 participants of all ages with open extremity fractures, excluding hand and finger fractures, recruited over 30 months:<BR/>111 cases treated with cefazolin<BR/>88 controls without treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-05 00:14:15 +1200" MODIFIED_BY="Helen HG Handoll">
<P>1. Intervention: Cefazolin 1 g intravenously every six hours for five days.<BR/>2. Control: no antibiotics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Early wound infection</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-07 15:45:50 +1200" MODIFIED_BY="Lesley ">
<P>Hand and feet open fractures excluded.<BR/>80% F/U at 1 year</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-07 15:45:49 +1200" MODIFIED_BY="Lesley " STUDY_ID="STD-Sloan-1987">
<CHAR_METHODS MODIFIED="2009-07-25 01:40:27 +1200" MODIFIED_BY="Lindsey Elstub">
<P>RCT<BR/>No blinding<BR/>Placebo controlled<BR/>Cultures for diagnosis<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-07 03:11:48 +1200" MODIFIED_BY="Lindsey Elstub">
<P>UK<BR/>40 adults with open finger fractures</P>
<P>85 planned, but stopped after 40 because of 30% infection rate in placebo group<BR/>Study continued with remaining three antibiotics groups - time?<BR/>
<BR/>30 cases treated with one of three regimens of cephradine<BR/>10 controls treated with placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-05 00:15:15 +1200" MODIFIED_BY="Helen HG Handoll">
<P>1. Intervention: Cephradine 500 mg orally every six hours for five days<BR/>2. Intervention: Cephradine 1 g intravenously followed by 500 mg orally every six hours for five days<BR/>3. Intervention: Cephradine 1 g intravenously followed by one dose of 1 g orally<BR/>4. Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Early wound infection: Swabs were taken if there was any evidence of infection (erythema, pus or exudate).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-07 15:45:49 +1200" MODIFIED_BY="Lesley ">
<P>Only fingers<BR/>F/U 5 days<BR/>8 lost to F/U</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-07 03:23:20 +1200" MODIFIED_BY="Lindsey Elstub" STUDY_ID="STD-Stevenson-2003">
<CHAR_METHODS MODIFIED="2009-08-07 03:23:20 +1200" MODIFIED_BY="Lindsey Elstub">
<P>RCT<BR/>Placebo controlled<BR/>Double blind<BR/>Cultures for diagnosis (infection was defined on clinical grounds)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-05 00:19:32 +1200" MODIFIED_BY="Helen HG Handoll">
<P>UK<BR/>200 randomised. 7 did not meet criteria on review, or were lost. 193 analysed.<BR/>98 treated with flucloxacillin<BR/>93 controls treated with placebo</P>
<P>Inclusion criteria: recent fracture of a distal phalanx in a finger with an overlying wound, including fractures associated with subungual hematoma bleeding externally or trephined as part of the treatment process.</P>
<P>Exclusion criteria: less than 16 years of age, wound was more than 12 hours old, history of diabetes or symptomatic peripheral vascular disease, taking oral steroids, fracture caused by a bite, already coincidentally taking an antibiotic or had a known allergy to penicillin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-05 00:15:07 +1200" MODIFIED_BY="Helen HG Handoll">
<P>1. Flucloxacillin 250 mg capsule<BR/>2. Lactose placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-01 17:03:40 +1300" MODIFIED_BY="[Empty name]">
<P>Infection, defined using clinical parameters of erythema, pain, swelling, wound discharge, presence of pus or cellulitis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-07 15:45:49 +1200" MODIFIED_BY="Lesley " STUDY_ID="STD-Suprock-1990">
<CHAR_METHODS MODIFIED="2009-07-25 01:40:36 +1200" MODIFIED_BY="Lindsey Elstub">
<P>CCT quasi-randomised (alternate days)<BR/>No blinding<BR/>No placebo<BR/>No cultures<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-07 03:09:11 +1200" MODIFIED_BY="Lindsey Elstub">
<P>USA<BR/>91 patients with open finger fractures recruited over 25 months<BR/>45 cases treated with cephalosporin, dicloxacillin or erythromycin<BR/>46 controls without treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Intervention: either a first generation cephalosporin, dicloxacillin or erythromycin for three days - dose and route of administration were not reported. <BR/>2. Control: no antibiotics.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Early wound infection: clinical signs of infection - full details not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-07 15:45:49 +1200" MODIFIED_BY="Lesley ">
<P>Only fingers<BR/>F/U up to one year<BR/>No antibiotic dosage reported.<BR/>Cultures done only if clinical suspicion.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>F/U: follow-up<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-03-14 15:20:44 +1300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Almanza-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>CCT. Non randomised comparison.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-14 15:20:44 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Altergott-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-14 15:20:44 +1300" MODIFIED_BY="[Empty name]">
<P>RCT. Antibiotic therapy versus no antibiotic for fingertip injuries in children. Only 39% of 146 randomised had fracture. No separate data presented. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-29 17:01:15 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cutler-1944">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-29 17:01:15 +1300" MODIFIED_BY="[Empty name]">
<P>CCT. Non randomised comparison. Fractures are not separated from soft tissue injuries only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miller-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT. All participants received an initial dose of antibiotics, then were randomised to more or no more antibiotics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peacock-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT. Fractures are not separated from soft tissue injuries only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-08-04 22:27:12 +1200" MODIFIED_BY="Helen HG Handoll">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-08-04 22:27:08 +1200" MODIFIED_BY="Helen HG Handoll" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-07 10:15:39 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bergman-1982">
<DESCRIPTION>
<P>"The patients were randomly allocated to treatment"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-07 10:17:52 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Braun-1987">
<DESCRIPTION>
<P>Unclear; no description given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-01 14:07:12 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dickey-1989">
<DESCRIPTION>
<P>Inadequate. Alternate days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-04 22:27:08 +1200" MODIFIED_BY="Helen HG Handoll" RESULT="UNKNOWN" STUDY_ID="STD-Patzakis-1974">
<DESCRIPTION>
<P>Consecutive patients "randomly assigned to one of three study groups: Group I, no antibiotics; Group II, penicillin and streptomycin; and Group III, cephalothin (Keflin)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-01 14:07:37 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rojczyk-1983">
<DESCRIPTION>
<P>Inadequate. Alternate days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-07 12:56:00 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sloan-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 06:03:08 +1300" MODIFIED_BY="Lindsey Elstub" RESULT="YES" STUDY_ID="STD-Stevenson-2003">
<DESCRIPTION>
<P>"Two hundred identical bottles of study medication were prepared in the hospital pharmacy department. The bottles were randomised into blocks of ten using a random number table and sequentially labelled. Each group of ten bottles consisted of five of placebo and five of flucloxacillin."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-01 14:36:40 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suprock-1990">
<DESCRIPTION>
<P>Inadequate. Alternate days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-08-04 22:27:12 +1200" MODIFIED_BY="Helen HG Handoll" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-25 01:37:21 +1200" MODIFIED_BY="Lindsey Elstub" RESULT="YES" STUDY_ID="STD-Bergman-1982">
<DESCRIPTION>
<P>"The drugs were packed in coded boxes according to random number, each box containing divided doses for a treatment period for one patient" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-22 15:44:22 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Braun-1987">
<DESCRIPTION>
<P>Placebo controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-01 14:04:18 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dickey-1989">
<DESCRIPTION>
<P>Inadequate. Alternate days.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-04 22:27:12 +1200" MODIFIED_BY="Helen HG Handoll" RESULT="UNKNOWN" STUDY_ID="STD-Patzakis-1974">
<DESCRIPTION>
<P>Consecutive patients "randomly assigned to one of three study groups: Group I, no antibiotics; Group II, penicillin and streptomycin; and Group III, cephalothin (Keflin)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-01 14:07:39 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rojczyk-1983">
<DESCRIPTION>
<P>Inadequate. Alternate days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-07 12:56:49 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sloan-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 06:03:10 +1300" MODIFIED_BY="Lindsey Elstub" RESULT="YES" STUDY_ID="STD-Stevenson-2003">
<DESCRIPTION>
<P>"Sealed code identifying each bottle was kept in the pharmacy department and not opened until completion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-01 14:36:34 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suprock-1990">
<DESCRIPTION>
<P>Inadequate. Alternate days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-03-15 17:17:43 +1300" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-01 14:47:31 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergman-1982">
<DESCRIPTION>
<P>Double blind. "The patients were treated with either dicloxacillin,<BR/>benzyl penicillin or saline (placebo)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-01 14:47:11 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-1987">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-01 14:08:06 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dickey-1989">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-01 14:03:14 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Patzakis-1974">
<DESCRIPTION>
<P>No placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-01 14:07:53 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rojczyk-1983">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-15 17:17:43 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sloan-1987">
<DESCRIPTION>
<P>Placebo controlled but insufficient information on early stop. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-01 17:05:02 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stevenson-2003">
<DESCRIPTION>
<P>"Each patient entered in the study was given the next sequential bottle containing the study medication and instructed to take two capsules four times daily for five days."<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-01 14:36:49 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suprock-1990">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-08-04 22:28:14 +1200" MODIFIED_BY="Helen HG Handoll">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-08-04 22:28:14 +1200" MODIFIED_BY="Helen HG Handoll" NO="1">
<TITLE MODIFIED="2008-09-26 04:35:35 +1200" MODIFIED_BY="Lindsey Elstub">Quality assessment tool</TITLE>
<TABLE COLS="2" ROWS="9">
<TR>
<TH>
<P>Items</P>
</TH>
<TH>
<P>Scores</P>
</TH>
</TR>
<TR>
<TD>
<P>A. Was the assigned treatment adequately concealed prior to allocation?<BR/>
</P>
</TD>
<TD>
<P>1 = states random, but no description, or quasi-randomisation<BR/>2 = small but real chance of disclosure of assignment<BR/>3 = method did not allow disclosure of assignment</P>
</TD>
</TR>
<TR>
<TD>
<P>B. Were the outcomes of patients who withdrew described and included in the analysis (intention-to-treat)?<BR/>
</P>
</TD>
<TD>
<P>1 = not mentioned<BR/>2 = states numbers and reasons for withdrawal, but analysis unmodified<BR/>3 = primary analysis based on all cases as randomised</P>
</TD>
</TR>
<TR>
<TD>
<P>C. Assessment of outcome. Were assessors of outcome blinded to treatment status?<BR/>
</P>
</TD>
<TD>
<P>1 = not done or not mentioned<BR/>2 = moderate chance of unblinding of assessors<BR/>3 = action taken to blind assessors, or outcomes such that bias is unlikely</P>
</TD>
</TR>
<TR>
<TD>
<P>D. Were treatment and control groups comparable at entry?<BR/>
</P>
</TD>
<TD>
<P>1 = large potential for confounding or not discussed<BR/>2 = confounding small; mentioned but not adjusted for<BR/>3 = unconfounded; good comparability of groups or confounding adjusted for</P>
</TD>
</TR>
<TR>
<TD>
<P>E. Was a placebo treatment assigned as part of the randomisation?<BR/>
</P>
</TD>
<TD>
<P>1 = no<BR/>3 = yes</P>
</TD>
</TR>
<TR>
<TD>
<P>F. Were exclusion criteria clearly defined?<BR/>
</P>
</TD>
<TD>
<P>1 = not defined<BR/>2 = poorly defined<BR/>3 = well defined</P>
</TD>
</TR>
<TR>
<TD>
<P>G. Was the method of assessment of wound infection stated?<BR/>
</P>
</TD>
<TD>
<P>1 = not stated<BR/>2 = clinical decision, or definite criteria without a microbiological diagnosis<BR/>3 = definite criteria including a microbiological diagnosis</P>
</TD>
</TR>
<TR>
<TD>
<P>H. Was the method and duration of surveillance stated?<BR/>
</P>
</TD>
<TD>
<P>1 = not stated, or not active<BR/>2 = active, but less than three months<BR/>3 = active, and at least one year</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-08-04 23:07:25 +1200" MODIFIED_BY="Helen HG Handoll">
<COMPARISON ID="CMP-001" MODIFIED="2009-08-04 23:07:25 +1200" MODIFIED_BY="Helen HG Handoll" NO="1">
<NAME>Any antibiotic treatment versus control</NAME>
<DICH_OUTCOME CHI2="6.696297048515932" CI_END="0.6540567684265686" CI_START="0.28634556455416976" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.43276581959020477" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.18438455573620527" LOG_CI_START="-0.5431095396488456" LOG_EFFECT_SIZE="-0.3637470476925254" METHOD="MH" MODIFIED="2009-07-29 12:00:41 +1200" MODIFIED_BY="Lesley " NO="1" P_CHI2="0.46117139208603186" P_Q="0.0" P_Z="7.043664137465102E-5" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="645" TOTAL_2="461" WEIGHT="99.99999999999999" Z="3.9748060209474683">
<NAME>Early wound infection</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>None</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9400464612803345" CI_END="0.6828528509478684" CI_START="0.14946060100676783" DF="2.0" EFFECT_SIZE="0.31946767833671885" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.16567287304829004" LOG_CI_START="-0.8254732757035749" LOG_EFFECT_SIZE="-0.49557307437593245" MODIFIED="2008-10-07 12:55:13 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.37907431630379784" P_Z="0.0032374881030152523" STUDIES="3" TAU2="0.0" TOTAL_1="201" TOTAL_2="169" WEIGHT="38.31717986228603" Z="2.944240026455635">
<NAME>Studies with lower risk of bias</NAME>
<DICH_DATA CI_END="1.0922118296365861" CI_START="0.10173036776948415" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.03830687602489545" LOG_CI_START="-0.9925493854642204" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="1" O_E="0.0" SE="0.6055300708194983" STUDY_ID="STD-Bergman-1982" TOTAL_1="60" TOTAL_2="30" VAR="0.36666666666666664" WEIGHT="12.812836401554245"/>
<DICH_DATA CI_END="0.7174625920998415" CI_START="0.040538407016267014" EFFECT_SIZE="0.17054263565891473" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.14420073775513892" LOG_CI_START="-1.3921333211989466" LOG_EFFECT_SIZE="-0.7681670294770427" ORDER="2" O_E="0.0" SE="0.733041776880808" STUDY_ID="STD-Braun-1987" TOTAL_1="43" TOTAL_2="44" VAR="0.5373502466525722" WEIGHT="18.998343629890776"/>
<DICH_DATA CI_END="3.1624113536138543" CI_START="0.16714724604081072" EFFECT_SIZE="0.7270408163265306" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.500018360531409" LOG_CI_START="-0.776900774555303" LOG_EFFECT_SIZE="-0.13844120701194704" MODIFIED="2008-10-01 17:11:22 +1300" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.7500686208015948" STUDY_ID="STD-Stevenson-2003" TOTAL_1="98" TOTAL_2="95" VAR="0.5626029359112065" WEIGHT="6.505999830841016"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8965444132383107" CI_END="0.8247301807973458" CI_START="0.3069563653392449" DF="4.0" EFFECT_SIZE="0.5031462796077614" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.08368811224672283" LOG_CI_START="-0.512923356246719" LOG_EFFECT_SIZE="-0.2983057342467209" MODIFIED="2009-07-29 12:00:41 +1200" MODIFIED_BY="Lesley " NO="2" P_CHI2="0.4201882169733874" P_Z="0.0064450940116563896" STUDIES="5" TAU2="0.0" TOTAL_1="444" TOTAL_2="292" WEIGHT="61.682820137713954" Z="2.7242334066368272">
<NAME>Studies with higher risk of bias</NAME>
<DICH_DATA CI_END="16.87973091851368" CI_START="0.06999367974849574" EFFECT_SIZE="1.0869565217391304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2273655192128514" LOG_CI_START="-1.154941173903962" LOG_EFFECT_SIZE="0.03621217265444471" ORDER="16" O_E="0.0" SE="1.3993787441451357" STUDY_ID="STD-Dickey-1989" TOTAL_1="46" TOTAL_2="50" VAR="1.9582608695652173" WEIGHT="1.534871027269519"/>
<DICH_DATA CI_END="1.0295132829574634" CI_START="0.20756230034600537" EFFECT_SIZE="0.46226415094339623" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.012631954332306667" LOG_CI_START="-0.6828515248048198" LOG_EFFECT_SIZE="-0.33510978523625656" ORDER="17" O_E="0.0" SE="0.4085304383438929" STUDY_ID="STD-Patzakis-1974" TOTAL_1="212" TOTAL_2="98" VAR="0.16689711905345328" WEIGHT="24.0963987809875"/>
<DICH_DATA CI_END="1.236237857447139" CI_START="0.22596169805491995" EFFECT_SIZE="0.5285285285285285" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.09210203890687223" LOG_CI_START="-0.6459651702912123" LOG_EFFECT_SIZE="-0.2769315656921701" ORDER="18" O_E="0.0" SE="0.4335443321745632" STUDY_ID="STD-Rojczyk-1983" TOTAL_1="111" TOTAL_2="88" VAR="0.18796068796068796" WEIGHT="21.440575486017906"/>
<DICH_DATA CI_END="0.9050571700467515" CI_START="0.0028391601410430495" EFFECT_SIZE="0.05069124423963134" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="-0.043323986704588445" LOG_CI_START="-2.54681011067602" LOG_EFFECT_SIZE="-1.2950670486903044" ORDER="17" O_E="0.0" SE="1.4705601416769958" STUDY_ID="STD-Sloan-1987" TOTAL_1="30" TOTAL_2="10" VAR="2.1625471302890658" WEIGHT="8.27495684267045"/>
<DICH_DATA CI_END="3.8403173394511825" CI_START="0.2720968553484879" EFFECT_SIZE="1.0222222222222221" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.584367113189965" LOG_CI_START="-0.5652764773775043" LOG_EFFECT_SIZE="0.009545317906230361" ORDER="20" O_E="0.0" SE="0.6753063359268853" STUDY_ID="STD-Suprock-1990" TOTAL_1="45" TOTAL_2="46" VAR="0.4560386473429952" WEIGHT="6.336018000768583"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.17123174547828" CI_END="-0.03291772602251454" CI_START="-0.10159021504819817" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.06725397053535635" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="53" I2="63.486957473919134" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2009-08-04 23:07:25 +1200" MODIFIED_BY="Helen HG Handoll" NO="2" P_CHI2="0.007667544011367822" P_Q="0.0" P_Z="1.2355815532561035E-4" Q="0.0" RANDOM="NO" SCALE="0.7073606876209712" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="645" TOTAL_2="461" WEIGHT="100.0" Z="3.8389568206073696">
<NAME>Early wound infection (risk difference)</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>None</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.189725361489426" CI_END="-0.033416592355211036" CI_START="-0.14751508885642722" DF="2.0" EFFECT_SIZE="-0.09046584060581914" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" I2="83.5927394531912" ID="CMP-001.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-08-04 23:06:15 +1200" MODIFIED_BY="Helen HG Handoll" NO="1" P_CHI2="0.002254427657382263" P_Z="0.001883499591754409" STUDIES="3" TAU2="0.0" TOTAL_1="201" TOTAL_2="169" WEIGHT="34.570460146138714" Z="3.1080127233167656">
<NAME>Studies with lower risk of bias</NAME>
<DICH_DATA CI_END="0.023100408072885548" CI_START="-0.28976707473955227" EFFECT_SIZE="-0.13333333333333336" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-04 23:06:15 +1200" MODIFIED_BY="Helen HG Handoll" ORDER="166" O_E="0.0" SE="0.07981459998252431" STUDY_ID="STD-Bergman-1982" TOTAL_1="60" TOTAL_2="30" VAR="0.00637037037037037" WEIGHT="7.683565081926359"/>
<DICH_DATA CI_END="-0.08034316702096186" CI_START="-0.3720881226196301" EFFECT_SIZE="-0.22621564482029596" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-04 23:06:15 +1200" MODIFIED_BY="Helen HG Handoll" ORDER="167" O_E="0.0" SE="0.07442610116816308" STUDY_ID="STD-Braun-1987" TOTAL_1="43" TOTAL_2="44" VAR="0.005539244535093645" WEIGHT="8.354773066094639"/>
<DICH_DATA CI_END="0.04136642145522051" CI_START="-0.06435245797509162" EFFECT_SIZE="-0.011493018259935553" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-04 23:06:15 +1200" MODIFIED_BY="Helen HG Handoll" ORDER="165" O_E="0.0" SE="0.026969597468170115" STUDY_ID="STD-Stevenson-2003" TOTAL_1="98" TOTAL_2="95" VAR="7.273591875951279E-4" WEIGHT="18.53212199811772"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.720406849548391" CI_END="-0.012031787530924778" CI_START="-0.0979476292377504" DF="4.0" EFFECT_SIZE="-0.05498970838433759" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" I2="48.189258960698666" ID="CMP-001.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-08-04 23:06:15 +1200" MODIFIED_BY="Helen HG Handoll" NO="2" P_CHI2="0.10237408501998713" P_Z="0.012110201529459774" STUDIES="5" TAU2="0.0" TOTAL_1="444" TOTAL_2="292" WEIGHT="65.42953985386129" Z="2.5089167681424103">
<NAME>Studies with higher risk of bias</NAME>
<DICH_DATA CI_END="0.05902630283466395" CI_START="-0.05554804196509874" EFFECT_SIZE="0.0017391304347826077" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-04 23:06:15 +1200" MODIFIED_BY="Helen HG Handoll" ORDER="169" O_E="0.0" SE="0.029228686267582085" STUDY_ID="STD-Dickey-1989" TOTAL_1="46" TOTAL_2="50" VAR="8.543161009287416E-4" WEIGHT="9.204270671057618"/>
<DICH_DATA CI_END="0.008905077861016547" CI_START="-0.1296212888737235" EFFECT_SIZE="-0.06035810550635348" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-04 23:06:15 +1200" MODIFIED_BY="Helen HG Handoll" ORDER="171" O_E="0.0" SE="0.03533900822347205" STUDY_ID="STD-Patzakis-1974" TOTAL_1="212" TOTAL_2="98" VAR="0.0012488455022186251" WEIGHT="25.747378732597102"/>
<DICH_DATA CI_END="0.022053273486862326" CI_START="-0.1506364020699909" EFFECT_SIZE="-0.06429156429156428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-04 23:06:15 +1200" MODIFIED_BY="Helen HG Handoll" ORDER="168" O_E="0.0" SE="0.04405429817052949" STUDY_ID="STD-Rojczyk-1983" TOTAL_1="111" TOTAL_2="88" VAR="0.0019407811872979184" WEIGHT="18.857553698556956"/>
<DICH_DATA CI_END="-0.021203041768324216" CI_START="-0.5787969582316758" EFFECT_SIZE="-0.3" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-04 23:06:15 +1200" MODIFIED_BY="Helen HG Handoll" ORDER="172" O_E="0.0" SE="0.14224595983946164" STUDY_ID="STD-Sloan-1987" TOTAL_1="30" TOTAL_2="10" VAR="0.020233913090649733" WEIGHT="2.8813369057223848"/>
<DICH_DATA CI_END="0.1183104299343685" CI_START="-0.11444569563485157" EFFECT_SIZE="0.00193236714975846" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-04 23:06:15 +1200" MODIFIED_BY="Helen HG Handoll" ORDER="170" O_E="0.0" SE="0.0593776537235303" STUDY_ID="STD-Suprock-1990" TOTAL_1="45" TOTAL_2="46" VAR="0.003525705761711472" WEIGHT="8.738999845927232"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.9029141749857725" CI_END="0.6859854350962268" CI_START="0.2658519571309446" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4270486746070692" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="42" I2="24.07863900393678" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.16368510517442764" LOG_CI_START="-0.5753601381783113" LOG_EFFECT_SIZE="-0.3695226216763695" METHOD="MH" MODIFIED="2009-08-04 23:06:19 +1200" MODIFIED_BY="Helen HG Handoll" NO="3" P_CHI2="0.2453029329957982" P_Q="0.0" P_Z="4.339006293686003E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="476" TOTAL_2="363" WEIGHT="99.99999999999999" Z="3.51855697769105">
<NAME>Early wound infection by location of open injury</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>None</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4000554574485986" CI_END="0.6792792097364515" CI_START="0.20634195049469847" DF="3.0" EFFECT_SIZE="0.37438455773110724" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="31" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.16795167737881359" LOG_CI_START="-0.6854124685065612" LOG_EFFECT_SIZE="-0.42668207294268745" MODIFIED="2009-03-15 17:19:04 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.49362449093282745" P_Z="0.0012281926223406511" STUDIES="4" TAU2="0.0" TOTAL_1="260" TOTAL_2="212" WEIGHT="72.011405238299" Z="3.2322506754337006">
<NAME>Open limb fracture excluding finger fractures</NAME>
<DICH_DATA CI_END="1.0922118296365861" CI_START="0.10173036776948415" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.03830687602489545" LOG_CI_START="-0.9925493854642204" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2009-03-15 16:08:32 +1300" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.6055300708194983" STUDY_ID="STD-Bergman-1982" TOTAL_1="60" TOTAL_2="30" VAR="0.36666666666666664" WEIGHT="16.84116019830141"/>
<DICH_DATA CI_END="0.7174625920998415" CI_START="0.040538407016267014" EFFECT_SIZE="0.17054263565891473" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.14420073775513892" LOG_CI_START="-1.3921333211989466" LOG_EFFECT_SIZE="-0.7681670294770427" ORDER="12" O_E="0.0" SE="0.733041776880808" STUDY_ID="STD-Braun-1987" TOTAL_1="43" TOTAL_2="44" VAR="0.5373502466525722" WEIGHT="24.97137546644692"/>
<DICH_DATA CI_END="16.87973091851368" CI_START="0.06999367974849574" EFFECT_SIZE="1.0869565217391304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2273655192128514" LOG_CI_START="-1.154941173903962" LOG_EFFECT_SIZE="0.03621217265444471" ORDER="15" O_E="0.0" SE="1.3993787441451357" STUDY_ID="STD-Dickey-1989" TOTAL_1="46" TOTAL_2="50" VAR="1.9582608695652173" WEIGHT="2.0174306487548566"/>
<DICH_DATA CI_END="1.236237857447139" CI_START="0.22596169805491995" EFFECT_SIZE="0.5285285285285285" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.09210203890687223" LOG_CI_START="-0.6459651702912123" LOG_EFFECT_SIZE="-0.2769315656921701" ORDER="18" O_E="0.0" SE="0.4335443321745632" STUDY_ID="STD-Rojczyk-1983" TOTAL_1="111" TOTAL_2="88" VAR="0.18796068796068796" WEIGHT="28.181438924795827"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.492240346424922" CI_END="1.231027167269388" CI_START="0.25706947103850797" DF="2.0" EFFECT_SIZE="0.5625473337631016" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="63.584987658053514" ID="CMP-001.03.02" LOG_CI_END="0.09026763738703711" LOG_CI_START="-0.5899494960788844" LOG_EFFECT_SIZE="-0.24984092934592358" MODIFIED="2009-03-15 16:32:00 +1300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06417641020074549" P_Z="0.14993155589193316" STUDIES="3" TAU2="0.0" TOTAL_1="216" TOTAL_2="151" WEIGHT="27.98859476170098" Z="1.4397732702996058">
<NAME>Open finger fractures</NAME>
<DICH_DATA CI_END="0.48158294004985625" CI_START="0.017318116940726304" EFFECT_SIZE="0.091324200913242" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="-0.31732890624657556" LOG_CI_START="-1.7614993321056986" LOG_EFFECT_SIZE="-1.0394141191761372" MODIFIED="2009-03-15 16:32:00 +1300" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.8483128569085505" STUDY_ID="STD-Sloan-1987" TOTAL_1="73" TOTAL_2="10" VAR="0.7196347031963469" WEIGHT="11.109078564542195"/>
<DICH_DATA CI_END="3.1624113536138543" CI_START="0.16714724604081072" EFFECT_SIZE="0.7270408163265306" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.500018360531409" LOG_CI_START="-0.776900774555303" LOG_EFFECT_SIZE="-0.13844120701194704" ORDER="10" O_E="0.0" SE="0.7500686208015948" STUDY_ID="STD-Stevenson-2003" TOTAL_1="98" TOTAL_2="95" VAR="0.5626029359112065" WEIGHT="8.551469945251494"/>
<DICH_DATA CI_END="3.8403173394511825" CI_START="0.2720968553484879" EFFECT_SIZE="1.0222222222222221" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.584367113189965" LOG_CI_START="-0.5652764773775043" LOG_EFFECT_SIZE="0.009545317906230361" ORDER="11" O_E="0.0" SE="0.6753063359268853" STUDY_ID="STD-Suprock-1990" TOTAL_1="45" TOTAL_2="46" VAR="0.4560386473429952" WEIGHT="8.32804625190729"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-08-04 22:27:13 +1200" MODIFIED_BY="Helen HG Handoll">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-08-04 22:27:13 +1200" MODIFIED_BY="Helen HG Handoll" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAMwAAAG8CAIAAAAdFd3QAAAQ5ElEQVR42u2dv04cSRCHRyIh2ICA
J/AzECFEgMh4JwgJkCDkLRCPYIEdGkdESPgWy0dAwN1ltg/N9XqtE1q6e2pmunqmer6fJkDrpVj3
fFt/erqrqwqhDKoRUhOQISBDQIYQkCEgQ0CGEJAhIEMIyBCQFTG4kx9eRkFxZL0/AxlSgez/gZ4m
cECWCTI8GcOhOLiMA5AhIENAhqRDPOElokBG+g9kQAZkCMiAbHQJGTkZQkCGgAw1RkwgQ+qJPzkZ
AjIgAzIgQ+RkQIaADAEZapuNMeMPZAjIqC6BDMmLSsIlkOXzZIRLhICsiLgJZEglXE52+ziQ5YaM
6hIBGZDZ54xwiRCQWXZjQMZAABmQWR9f5smADAEZAjIki5g1M/5INfFnMhbIgAzIgAzIkCQn47ES
QkCGgAwJw2WS0bYVfIEsU+KvZNPEvQMy25DVFo4GAzLzkOHJgKzSy8mADCEgKy4Qk5MRMZPl5ua6
bABZJn+T/NklORlSh4ycDOWAjHCJ/CjoJf54MqReXQIZAjKUJVZqLMQgJ0P+RROTGnMgyx3UJrg3
DsgMQ2ZlRyeQDTOF0X/MDU3zApl5HwlkCMiArLhADGRowl8GBgIBWQlBLXnaxIw/0k3PeXaJgAzI
gAzImGggJ0Mj8pF4MgRkQJaXhuThEsiQ4j5vVsYidcjslT7QYLG6BDKUiVrCJUJANoTjATKkm/hP
EF8gswrZysNQVsYCmTpkNWv8SciSBzUgQ1ndJBtJEF8GIMsVMWuOh0bm0nN6YSBdyEj8EZAB2XCz
GCYCMZAhXXyBDFFdoqizYRUGylcHJLdGuETpOeMoQgRkQDZcTkZ1iRCQISBDjeFS9XglICPTrznv
EuWoJWmCh4AMyOynZarZHpAhqkuEgMx6uKyVD4sAsqkn/hlarJOTARmQISADMqYwyMkQAjIEZBNJ
y1jjj0j8gQzIgAzlhIzqEq0O8fgzJyBDQIYQkCEgQ0CGxnzzWH6NlBYtKt01xQf5oKBHWOiHEUKm
t0UUyIDMbzOVAwYyw5Alz8l0QzA0ZEvPTXxaIENMYaBoAOIBOdKKknrnXSbHN/nHBrLcnsyKj4zU
LkBGINayDGSW4ubIczIgs+pvbB2q6sUXyGxAVk9ycSyQ2YPsf6fIKgzk4cxouOTZJdWlenWJJ6Nc
VZ/mBTJ7QIwTBSArNsZN4YsBZIY5o7pEupAZmuYFMktzARHI6hHPwAGZeY84/mcJQFYIZ4RLwqWN
R0BKnxbIsmb6hh4rJfzMQJa7ltRevzrCzwxkViEzZBnIcic6Vnxk2j3DQAa+VJeojC8DA5HB39Rm
1/iTk9lI/A21WGepD5ANUF0CGZABGZxZm8LgsRJiCgMhIBtwFsCEyyFc2s79U6VN5vAFsnyEKdVu
hEsgswQZixapAQmXCAHZeIZ7zJZXHueznsxexBy55VAhTE5mgy2Vc9c0T54DMnt1pd5TSyDDk+HJ
gIycTH9yBMioLpnCQMU4cgYCARkCMoSADAGZ5bFDTdMcQNYLMixLLAMZKAAZkAEZkGEZyIAMyIAM
yFCfG/by8vzXX8ePjzsPDxt//FHN57M//9x6fj56eXnqafn55/Px/Hjn887Gh43qfTW7nm192jr6
cvT0Y4yWgUwLsn/+OX942HRsvb0cc3//fdbZ8vm3882Pm46At5cj4+zr6CwDmQpkzl158Xp9ufd0
sOyciheC15d7z6gsA1l6yJwPayRseYX8Wciy8zSNHCyvkNfJb7kXZLaaiHg/ebcX48Pq8rDXUfLq
qtrdrdbXF9fBQXVzsxo3//33UWjZZUuhWOaNbo/fh7ecALI8ZUtPwiKf09v9MP5i43/ZZfqvMXr3
bvEBLi+ri4vFD9vboqDptezycSEHkdCW2bIiZG8dwMqWh7ebIF7vJo3wETIbgaAzZI0j6H3R1ZLe
yHh3t/iQzp+tvO7qTaFlV/F5bvlSPhRcVTi4ZS3IQnfR2z1V8nNbs62+DMkhW85WrFy3t9XeXrW2
Vp2erv7TfD4TWl7OKchRmF0Pb1krJ2t1F+VvkAMt/zLEvW9by0t53dj+/sLy4aE//Zcy7YXgtd7Q
MLhlRU/2Fr4kkMnNShJ/OaytIPN6MufDnO7vPYThyfqGSwk3fd7QDbJWdiS/LsnJQhc5WcqcTJ5R
xS309GT9g3Wr6nJ5LSWfkqW6bJ4niydqrQLW23DZ35PJP3N8IlAyTxaHjHmygZ/MMOPPjH/fCdIC
Hmfx7NKGJysVsvr3KoyN8CqMk86Wndfx14O/YtnJw+gsA5lirA+tJ/PmYa0sh1Z9ebOlwS0D2RgT
SlbGIiADMiADMiADMgRkQAZkQDYpyBBdffBkeDIgAzIEZEAGZEAGZFgGMlAAMvOQ6XX1sdUvCMi0
INPr6mOuXxCQqUCmtzLW4ppbIEsPmd4af4u7BwaALH8voGF3KyXs6mOxX9BgkOUpdl7/90J/UaMX
hl5XH4v9gsYFmbftj3DHr3ZXn1Z70/W6+ljsFzQ6yBLuQRf6To02BXpdfSz2CxpXTtaISKpeGG27
+rSFTK+rj8V+QWMMl14W00JWt2x3kMSTJenqY7Ff0HghG09Xnw4NV/S6+ljsF2QAMkl/xs7hsrbW
1cdiv6BR52RvI1qdvatPN8j0uvpY7BfEjD8z/oXO+E8Bsppnl0CWAbJas6uPuX5BQKYFWa3Z1cdW
vyAgU4QMy0AGCkAGZECGgAzIgAzIgAzIkGRYEV198GR4MiADMgRkQAZkQAZkWAYyUAAy85D9fH6e
Hx9/3tn5sLHxvqquZ7NPW1tfjo5+PD1NyjKQaUH27fz84+amd/Gfu39fz86mYxnIVCBzX/3Glczu
PROxDGTpIXP+QLjxJ+QbSrKcD7L4geWqWWrP3UqR8fG+7nKaUMTxxqDvj48FW84NWQd6+n+wPl19
urX6cVlzmy2M/gBUjOUhIYvcS8lWcuH+3p5dfbpB5uqyVjfM1W4FWx4dZK1+8DIkQUEbsmXlL7+u
Z7OCLY8XMiFGod5mQsgau/qE3hkf1lBPiXCDnJIt24BM0mKzFWR1m3YH3m4JeLICPVn8PR0gSxUZ
ycnMVJc9c7K28yBUlyVXl5J5sg7VZYfJNubJypwnG/AJDzP+U5nxL4+wmmeXU/NkI4Tb+YZQ1eZe
fzg5mY5lIFP0oKG1Wd6cpmDLQDbGMM3KWARkQAZkQAZkQIaADMiADMgmBRmiqw+eDE8GZECGgAzI
gAzIgAzLQAYKQGYestAJSC8vT6O1TFcfS5D9OsttM3yW29kILdPVxxJkFs+7ZGWsJcgsntxrY42/
8AlDh/Qzsh+z869L9gw3/jnJSeFXV9XubrW+vrgODqqbm2RnkCe0bGa3Uv8j4jUKImFXn/h/pBVk
Lh9/fbPfvVv8+uVldXGx+GF7WxTaMls2s++ycTfl242ToZ4Djbsv4z0sIm9uhCzS00A4rK7i88av
u7uFHed1Vl53VeHgls3sII/0NYm/KH+zfEO5nH5JXG4Fmfd08Nvbam+vWlurTk9X/2k+nw1u2Uwv
DElO1ghZ5M0SWNvSrwGZ19ns7y/+1uGhP0kf3LKZrj7Nf0Pcua5tAG1czBSKgHHIGlGW+xvnaZzu
7z0c9PRkSSxb8mSNrzd26WkbLjvXgML8LO6bW2VOoat/TtbfstWcLB6eJMlZ5pysQ39kSQ24vJaS
T5xmtmy1uoyHp8bqsm7TwrNbuOzfhFsymxVHoc88WULLdPVhxp8ZfyDziWeXQKYOWf17rcRGeK3E
yQgt09XHGGR1eNWXN1saiWW6+hiDDMtABgpABmRAhoAMyIAMyIAMyJBkWBFdffBkeDIgAzIEZEAG
ZEAGZFgGMlAAMvOQaXTIsWgZyLQgU+qQY9EykKlAxnmXQKYLGSf3ZoJM/syhZ0LawTJnkGezrA5Z
nrqmsX1Qq/3DdZtNnZn3MFq0PCRkks4DjR4x0iMj9Ia0PGXejW3R8mCQdetFEEKqbccKbcj0+kpY
tDxYTtaqO0bonZGeP0LIQs0WGwNufFj1OuRYtJzPk3XrqhL/lUjPH2HijycrwZNJmJNAFo+b3Ro8
kZMVmJN1gEyInV5ORnU50epSiCzzZJOYJ0s+p5phyo0Z/5K7+lgkrObZpTlPZlGDdMixaBnIFB2w
Rocci5aBLFOUn7JlIAMFIAMyIAMyLAMZkAEZkAEZig8roqsPngxPBmRAhoAMyIAMyIAMy0AGCkBm
HrLQCUgvL0+TsgxkWpD9OsttM3yW29l0LAOZCmQWz7vUswxk6SGzeHKvnuXBIGvcWa6KgnBjUuMz
E8lJ4VdX1e5utb6+uA4OqpubZGeQm7A8GGSRvgFKNIf+usbmXpc1v74l794tPsDlZXVxsfhhe1sU
gIqxPGrI5M6mDrerSNXVp9W+S1eXeaPM3d3iQzrfsPK6q90KtjwWyIS3PPSidlefVl02nLyng9/e
Vnt71dpadXq6+k/z+axgy+PNyeTBS5LS9e/q0woyr0vY319YPjz0p9IFWx5LdRlvfhHKxDtDVrfs
6pPEkzl/4HR/77lbPf3NyC2PNydL2BOl7tfVp7FXqDy/CV39M6cxW7YKWU9P1grWDpCtVGrLayn5
9GYxlkc9TxapLvt7slZdfdpCtjLnFL9hfWazTFhmxp8Z/6Jn/MuGrObZJZBlgKz+vaJhI7yi4WQ6
loFMC7I6vDbLm9MUbBnIFCHDMpCBApABGZAhIAMyIAMyIAMyJBlWRFcfPBmeDMiADAEZkAEZkAEZ
loEMFIDMPGTPP5+P58c7n3c2PmxU76vZ9Wzr09bRl6OnH0+TsgxkWpCdfzvf/LjpPdHP3b+zr2fT
sQxkKpC5r37j8aTuPROxDGTpIXP+QHiad8g3lGS5BWQ5+/Ck5aDPceMdziB3OU0o4nhj0OP3x4It
t4AsZx8eJU+jsXPY+6LLmoV3KxKAirHcF7K3HQMat93K2/Ik6erT+MXQaB3l6jLPjVnKd8Nc7Vaw
5e6QSW6S5JU6sB08bVefzJAtK3/5DZtdzwq2nDIni7zYM051iH3C363FDVda5WT+W/Vab+5ZwZa7
V5eh/hTeiCl5j/fneBODbJDhyTJ5slYtUkJRUu6fEoa5OkWnRXKyAXKyVh3FVGu9DnBQXY60uozk
ZJHKMZTfCCmUV5cRniIfm3mycc2TIWb8c8z4o1bDyrNLIFOHbOkb/FXbr4hz8nAyHctApgVZHV6b
5c1pCrYMZIqQYRnIQAHIgAzIEJABGZABGZABGZIMK6KrD54MTwZkQIaADMiADMiADMtABgpAZh6y
n8/P8+Pjzzs7HzY23lfV9Wz2aWvry9HRj6enSVkGMi3Ivp2ff9zc9C7+c/fv69nZdCwDmQpk7qvf
uJLZvWciloEsPWTOHwg3/oR8Q0mW00MmeciQOTHqeQZ5291KLqcJRRxvDPr++Fiw5fSQtTolPg9k
8V16GvsuXdbcZgujPwAVYzkfZPFOGZHWLBHvEofGay0PZK4ua3XDXO1WsGV1yBrva6inhuTGC1sl
5IdsWfnLr+vZrGDL+XKy/vc1QpLXXQn9awfKG4c11FMi3CCnZMvq1WXC3hZxyBoXM4USNW/LBTzZ
qD1Zh5wslSeTh8vGfyIns5STNQajDt2Bxp+TUV0ONk8WCkbxdto9q0vmyQqcJ0s7icqMPzP+QMaz
y9FDVoAaVzSEqjb3+sPJyXQsA5miMw6tzfLmNAVbBrIxRnxWxiIgAzIgAzIgAzIEZEAGZEA2KcgQ
XX3QmL6NDAQCMgRkCAEZAjIEZAgBGTIAGUKq+g8lX5kfHoYaoAAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-07-29 12:00:42 +1200" MODIFIED_BY="Lesley " NO="2" REF_ID="CMP-001.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Any antibiotic treatment versus control, outcome: 1.1 Early wound infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-08-08 10:46:30 +1200" MODIFIED_BY="Lesley ">
<APPENDIX ID="APP-01" MODIFIED="2009-08-08 10:46:30 +1200" MODIFIED_BY="Lesley " NO="1">
<TITLE MODIFIED="2009-07-26 20:57:52 +1200" MODIFIED_BY="Lesley ">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-08 10:46:30 +1200" MODIFIED_BY="Lesley ">
<SUBSECTION>
<HEADING LEVEL="3">
<I>The </I>Cochrane Library (Wiley InterScience interface)</HEADING>
<P>#1 MeSH descriptor Antibiotic Prophylaxis, this term only<BR/>#2 MeSH descriptor Anti-Bacterial Agents explode all trees<BR/>#3 (antibiotic* or antimicrob*):ti,ab,kw in Clinical Trials<BR/>#4 (#1 OR #2 OR #3)<BR/>#5 MeSH descriptor Infection, this term only<BR/>#6 MeSH descriptor Wound Infection explode all trees<BR/>#7 MeSH descriptor Sepsis explode all trees<BR/>#8 (infect*):ti,ab,kw in Clinical Trials<BR/>#9 (#5 OR #6 OR #7 OR #8)<BR/>#10 MeSH descriptor Fractures, Bone explode all trees<BR/>#11 MeSH descriptor Fracture Fixation explode all trees<BR/>#12 (fractur*):ti,ab,kw in Clinical Trials<BR/>#13 (#10 OR #11 OR #12)<BR/>#14 (#4 AND #9 AND #13) (99 records identified)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">
<I>MEDLINE (Ovid interface) </I>
</HEADING>
<P>1    Antibiotic Prophylaxis/<BR/>2    exp Antibiotics/<BR/>3    (antibiotic$ or antimicrob$).tw.<BR/>4    or/1-3<BR/>5    Infection/<BR/>6    exp Wound Infection/<BR/>7    Sepsis/<BR/>8    infect$.tw.<BR/>9    or/5-8<BR/>10    exp Fractures, Bone/<BR/>11    exp Fracture Fixation/<BR/>12    fractur$.tw.<BR/>13    or/10-12<BR/>14    and/4,9,13<BR/>15    Randomized Controlled Trial.pt.<BR/>16    Controlled Clinical Trial.pt.<BR/>17    randomized.ab.<BR/>18    placebo.ab.<BR/>19    drug therapy.fs.<BR/>20    randomly.ab.<BR/>21    trial.ab.<BR/>22    groups.ab.<BR/>23    or/15-22<BR/>24    exp Animals/ not Humans/<BR/>25    23 not 24<BR/>26    and/14,25 (515 records identified)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE (Ovid interface)</HEADING>
<P>1     exp Antibiotic Agent/<BR/>2     (antibiotic$ or antimicrob$).tw.<BR/>3     or/1-2<BR/>4     exp Infection/<BR/>5     Infection Prevention/<BR/>6     Infection Complication/<BR/>7     or/4-6<BR/>8     exp Fracture/<BR/>9     exp Fracture Treatment/<BR/>10     fractur$.tw.<BR/>11     or/8-10<BR/>12     and/3,7,11<BR/>13     exp Randomized Controlled Trial/<BR/>14     exp Double Blind Procedure/<BR/>15     exp Single Blind Procedure/<BR/>16     exp Crossover Procedure/<BR/>17     Controlled Study/<BR/>18     or/13-17<BR/>19     ((clinical or controlled or comparative or placebo or prospective$ or randomi#ed) adj3 (trial or study)).tw.<BR/>20     (random$ adj7 (allocat$ or allot$ or assign$ or basis$ or divid$ or order$)).tw.<BR/>21     ((singl$ or doubl$ or trebl$ or tripl$) adj7 (blind$ or mask$)).tw.<BR/>22     (cross?over$ or (cross adj1 over$)).tw.<BR/>23     ((allocat$ or allot$ or assign$ or divid$) adj3 (condition$ or experiment$ or intervention$ or treatment$ or therap$ or control$ or group$)).tw.<BR/>24     or/19-23<BR/>25     or/18,24<BR/>26     limit 25 to human<BR/>27     and/12,26   (524 records identified)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LILACS (Clinical Trials in LILACS)</HEADING>
<P>((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CONTROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw clinic$)) AND NOT ((CT ANIMALS OR MH ANIMALS OR CT RABBITS OR CT MICE OR MH RATS OR MH PRIMATES OR MH DOGS OR MH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Palavras] and (antibiotic$ OR antimicrob$) [Palavras] and (fractur$) [Palavras] (1 record identified)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">International Pharmaceutical Abstracts (Ovid interface)</HEADING>
<P>1. (antibiotic$ or antimicrob$ or infect$ or septic or sepsis).tw.<BR/>2. (fractur$ and open).tw.<BR/>3. and/1-2 (10 records identified)</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-08-08 10:44:05 +1200" MODIFIED_BY="Lesley " NO="2">
<TITLE MODIFIED="2009-08-08 10:44:05 +1200" MODIFIED_BY="Lesley ">Search strategy for MEDLINE (OVID WEB) in previous versions</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-25 23:58:40 +1200" MODIFIED_BY="[Empty name]">
<P>1. Antibiotic Prophylaxis/<BR/>2. exp Antibiotics/<BR/>3. (antibiotic$ or antimicrob$).tw.<BR/>4. or/1-3<BR/>5. Infection/<BR/>6. exp Wound Infection/<BR/>7. Sepsis/<BR/>8. infect$.tw.<BR/>9. or/5-8<BR/>10. and/4,9<BR/>11. Fractures, Open/<BR/>12. exp Fractures/<BR/>13. (open or compound).tw.<BR/>14. and/12-13<BR/>15. (infect$ adj3 (bone$ or fracture$)).tw<BR/>16. or/11,14,15<BR/>17. and/10,16</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>